Drug Trial Radar · NCT04533529
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
588
Actual
Start
Sep 16, 2020
Primary completion
Apr 25, 2023
Study completion Apr 30, 2024
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Aug 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with an selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) in double-blind treatment phase and to assess the long-term safety and tolerability of seltorexant as adjunctive therapy to an antidepressant in participants with major depressive disorder (MDD) in open-label treatment phase.
Conditions
- Depressive Disorder, Major
Interventions
SeltorexantDrug
Seltorexant tablet will be administered orally once daily.
PlaceboDrug
Matching placebo tablet will be administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1Time frame: Baseline (Day 1), Day 43
- Open Label (OL) Treatment Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)
- OL Treatment Phase: Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)Time frame: From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)
- OL Treatment Phase: Change From Baseline in Vital Signs: Blood PressureTime frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
- OL Treatment Phase: Change From Baseline: Body Mass Index (BMI)Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
- OL Treatment Phase: Change From Baseline in Vital Signs: TemperatureTime frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
- OL Treatment Phase: Change From Baseline in Vital Signs: Pulse RateTime frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
- OL Treatment Phase: Change From Baseline in WeightTime frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
- OL Treatment Phase: Change From Baseline in Waist CircumferenceTime frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
- OL Treatment Phase: Number of Participants With Shift From Baseline in Suicidal Ideation and Behavior Using the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: From DB Baseline (Day 1) up to Week 52
- OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Start of OL Follow UpTime frame: Start of OL Follow Up (Week 52)
- OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 1Time frame: Follow up Visit 1: 1 day after end of OL phase (Week 52.14)
- OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 2Time frame: Follow Up Visit 2: 2 weeks after end of OL phase (Week 54)
- OL Treatment Phase: Number of Participants With Electrocardiogram (ECG) AbnormalitiesTime frame: Week 52
- OL Treatment Phase: Number of Participants With Clinically Significant Laboratory AbnormalitiesTime frame: From DB Baseline (Day 1) to Week 52
- OL Treatment Phase: Number of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) ScoreTime frame: Week 52
Locations
122 sites in 11 countries. Site status is shown where the registry gives one.
Advanced Research Center Inc
Anaheim, California
Synexus
Cerritos, California
Irvine Clinical Research
Irvine, California
Omega Clinical Trials LLC
La Habra, California
Synergy East
Lemon Grove, California
Semel Institute for Neuroscience and Human Behavior
Los Angeles, California
Catalina Research Institute
Montclair, California
Pacific Research Partners
Oakland, California
North County Clinical Research
Oceanside, California
Syrentis Clinical Research
Santa Ana, California
Viking Pharmaceutical Trials Inc. dba Viking Clinical Research
Temecula, California
Connecticut Clinical Trials LLC
Cromwell, Connecticut
University of Connecticut Health Center
Farmington, Connecticut
Sarkis Clinical Trials
Gainesville, Florida
Clinical NeuroScience Solutions Inc
Jacksonville, Florida
Pharmax Research Clinic Inc
Miami, Florida
Medical Research Center of Miami II Inc
Miami, Florida
Phoenix Medical Research, Inc.
Miami, Florida
Galiz Research
Miami Springs, Florida
Bravo Health Care Center
North Bay Village, Florida
APG Research LLC
Orlando, Florida
Combined Research Orlando
Orlando, Florida
Nova Psychiatry INC
Orlando, Florida
Revive Research Institute
Elgin, Illinois
Joliet Center for Clinical Research
Joliet, Illinois
Baber Research Group
Naperville, Illinois
American Medical Research, Inc.
Oak Brook, Illinois
Southern Illinois University School of Medicine
Springfield, Illinois
Louisiana Clinical Research
Shreveport, Louisiana
Adams Clinical
Watertown, Massachusetts
Neurobehavioral Medicine Group
Bloomfield Hills, Michigan
Midwest Research Group - St. Charles Psychiatric Associates
Saint Charles, Missouri
Mid-America Clinical Research, LLC
St Louis, Missouri
PsychCare Consultants Research
St Louis, Missouri
Premier Psychiatric Research Institute, LLC
Lincoln, Nebraska
Altea Research Institute
Las Vegas, Nevada
Hassman Research Institute, LLC.
Berlin, New Jersey
Synexus Clinical Research US Inc
Jamaica, New York
Bioscience Research LLC
Mount Kisco, New York
Haidar Almhana Nieding
Avon Lake, Ohio
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.